Sort by
Refine Your Search
-
Listed
-
Employer
-
Field
-
of Medical Research. The laboratory specialises in single-cell RNA sequencing, spatial transcriptomics and computational pipelines applied to patient biospecimens to understand the complexity of intestinal
-
ANSTO (Australia), Imperial College London (UK), and Tokamak Energy (UK), is launching a groundbreaking research program focused on developing new materials for compact tokamak reactors. We are recruiting
-
these ideas to areas such as Computer Vision, AI, social network modelling (and related areas) will be a plus: but the candidate must engage with the theoretical aspects of the project. The position requires a
-
of our professional staff cohort, you will be actively involved in working towards our vision of a better world. By supporting the academic endeavour across teaching, research, and the student life
-
contribution of 17% superannuation applies. 24 Months Fixed term Part time position until Oct 2027. This postdoctoral position in computational cognitive science and data science offers an exciting opportunity
-
believe everyone has the right to good health. As the oldest and largest health management program in Australia, our School is a pioneer in public health, global health, infectious diseases intelligence
-
) Sydney, in partnership with ANSTO (Australia), Imperial College London (UK), and Tokamak Energy (UK), is launching a groundbreaking research program focused on developing new materials for compact tokamak
-
tools in combustion. Our computational codes are also used by various international research institutions. Both experimental and numerical projects are conducted in parallel providing a platform for
-
shielding, radiation damage, particle transport. Computational skills allowing to compose or modify comprehensive simulation open-source codes. Experience in data analysis and simulations of complex and
-
Doctoral Scientist position. This position will report to Professor Jose Polo, Lead of the Cancer Epigenetics Program at the South Australian Immunogenomics Cancer Institute (SAiGENCI) and the Inaugural